Cenovus Energy Inc vs Illumina, Inc. — how do they compare? Cenovus Energy Inc trades at $31.72 (market cap $57.90B), while Illumina, Inc. trades at $268.39 (market cap $39.95B). The key difference: Cenovus Energy Inc is the larger of the two by market cap, and Cenovus Energy Inc pays a 1.97% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cenovus Energy Inc for 46 Days and Illumina, Inc. for 83 Days on average.
| CVE | ILMN | |
|---|---|---|
Market Cap | $57.90B | $39.95B |
Volume | 7,863,588 | 3,169,503 |
Sector | Energy | Health |
52-Week High | $33.92 | $293.69 |
52-Week Low | $15.85 | $91.00 |
Typical Hold Time | 46 Days | 83 Days |
Enterprise Value | $63.84B | $41.31B |
Dividend Yield | 1.97% | — |
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $30.63, down 1.95% on the day, with a bearish technical signal and neutral oscillators. The stock shows strong profitability with a 20.96% ROE and 11.48% net margin, supported by recent earnings beats. Cash flow trends indicate operational strength, though net cash flow was negative $353 million in 2025. Analyst sentiment is mixed with 40.74% buy ratings, while recent news highlights growth potential and value attributes.
Outlook: CVE offers value with a low P/E of 12.43 and solid earnings growth projections, but faces headwinds from volatile oil prices and mixed technical indicators. Risks include energy market fluctuations and debt levels, though institutional interest remains steady. The stock presents a balanced opportunity for value investors seeking energy exposure.
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →